^(89)Sr治疗转移性骨肿瘤骨痛的临床应用  

The clinical application of ^(89)Sr in the treatment of metastatic bone pain

作　　者：金稚奎[1] 周大庆[1] 曾琴[1] 张强[1] 陈少萍[1] 

机构地区：[1]江苏省肿瘤医院,南京210009

出　　处：《核技术》2001年第5期365-369,共5页Nuclear Techniques

摘　　要：用8 9Sr治疗转移性骨癌 80例以评价镇痛疗效 ,毒副作用和使用剂量。在 17例血像资料完整的病例中 ,7例剂量为 1.11— 1.4 8MBq kg的白细胞和血小板计数治疗前后未见显著差异 ,10例剂量为 1.4 8— 2 .2 2MBq kg的血象治疗过程中有轻度改变 ,低谷时平均下降 14.1%和 2 4 .1%。89Sr治疗后 ,2 5 80例 ( 31.2 5% )疼痛消失 ( 4级 ) ;34 80例 ( 4 2 .5% )疼痛显著减轻 ( 3级 ) ;13 80例 ( 16.2 5% )疼痛轻度减轻 ( 2级 ) ;8 80例 ( 10 .0 % )疼痛无变甚至加剧 ( 1级 )。89Sr最佳冶疗剂量范围为 1.11— 1.4 8MBq kg。Clinical application of 80 patients treated with 89 Sr for metastatic bony pain was reported the toxic effet and dosage was also evaluated. Of the 17 cases with complete blood sample examination, 7 cases with the dosage of 1.11—1.48MBq/kg showed no changes in leukocyte and platelet count. 10 cases with the dosage of 1.48—2.22MBq/kg showed slight decline 14% and 23% respectively in leukocyte and platelet count. 5—6 weeks after 89 Sr treatment. As to the pain relief 25 cases 31.25% complete pain free (grade 4), 34 (42.5%) are of significant pain decrease (grade 3), 13 (16.25%) are of slight pain decrease (grade 2), 8 (10.0%) are of no change or even pain aggravated (grade 1), the total efficacy of 89 Sr was 90.0% and the significant efficacy (complete pain free + significant pain relief) was 73.75%. The optimal dose of our study was within the range of 1.11—1.48MBq/kg. Thereby, it was concluded 89 Sr was effective for relief of the metastatic bony pain.

关 键 词：放射治疗 骨转移肿瘤 骨痛 锶89 

分 类 号：R738.1[医药卫生—肿瘤] R730.55[医药卫生—临床医学]